Norris Medicines
NORRISMEDICINESLTD NSE
Norris Medicines
Commercial ServicesNSE: NORRISMEDICINESLTD BSE: 524414 Trading & Distributors
Key Fundamentals
MicrocapTrading & DistributorsCommercial ServicesMarket Cap
₹15.22 Cr
Volatility
Moderate
P/E Ratio
-39.2
EBITDA
₹0.66 Cr
Return on Equity
8.32%
Debt to Equity
0
Book Value
₹-15.07
EPS
₹0
52W High
₹19.63
52W Low
₹12
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Debtor days have improved from 69.8 to 52.5 days.
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -7.87% over past five years.
- Promoter holding is low: 34.0%
Growth Rate
Revenue Growth
37.8% higher than
3Y
Net Income Growth
-76.67% lower than
3Y
Cash Flow Change
200% higher than
3Y
ROE
-4.48% lower than
3Y
ROCE
37.56% higher than
3Y
EBITDA Margin (Avg.)
-335% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.95 | 2.56 | 0.65 | 1.49 | 0.72 | 1.27 | 1.11 | 2.72 | 1.46 | 2 | 3.27 | 1.41 | 0.92 |
| Expenses | 1.33 | 2.8 | 0.69 | 1.01 | 0.88 | 1.42 | 1.14 | 2.65 | 1.56 | 2.49 | 2.32 | 1.11 | 1.2 |
| Operating Profit | -0.38 | -0.24 | -0.04 | 0.48 | -0.16 | -0.15 | -0.03 | 0.07 | -0.1 | -0.49 | 0.95 | 0.3 | -0.28 |
| OPM % | -40% | -9.38% | -6.15% | 32.21% | -22.22% | -11.81% | -2.7% | 2.57% | -6.85% | -24.5% | 29.05% | 21.28% | -30.43% |
| Other Income | 0 | 0 | 0 | 0.03 | 0.01 | 0 | 0 | 0.05 | 0.02 | 0 | 0 | 0.02 | 0 |
| Interest | 0.09 | 0.09 | 0.09 | 0.11 | 0.08 | 0.08 | 0.12 | 0.15 | 0.11 | 0.11 | 0.13 | 0.15 | 0 |
| Depreciation | 0.14 | 0.14 | 0.14 | 0.14 | 0.13 | 0.13 | 0.13 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 |
| PBT | -0.61 | -0.47 | -0.27 | 0.26 | -0.36 | -0.36 | -0.28 | -0.17 | -0.31 | -0.72 | 0.7 | 0.05 | -0.39 |
| Tax % | 0% | 0% | 0% | 34.62% | 0% | 0% | 0% | 35.29% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.61 | -0.48 | -0.27 | 0.17 | -0.37 | -0.36 | -0.28 | -0.23 | -0.31 | -0.72 | 0.7 | 0.05 | -0.4 |
| EPS in Rs | -0.61 | -0.48 | -0.27 | 0.17 | -0.37 | -0.36 | -0.28 | -0.23 | -0.31 | -0.72 | 0.7 | 0.05 | -0.4 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.68 | 18.86 | 20.46 | 13.57 | 16.26 | 7.84 | 12.25 | 9.44 | 8.36 | 5.64 | 5.82 | 8.13 | 7.6 |
| Expenses | 16.97 | 18.03 | 20.46 | 15.49 | 16.87 | 10 | 14 | 9.52 | 7.43 | 5.81 | 6.08 | 7.47 | 7.12 |
| Operating Profit | 1.71 | 0.83 | 0 | -1.92 | -0.61 | -2.16 | -1.75 | -0.08 | 0.93 | -0.17 | -0.26 | 0.66 | 0.48 |
| OPM % | 9.15% | 4.4% | 0% | -14.15% | -3.75% | -27.55% | -14.29% | -0.85% | 11.12% | -3.01% | -4.47% | 8.12% | 6.32% |
| Other Income | 0.15 | 0.3 | 0.06 | 0.14 | 0.04 | 0.09 | 0.05 | 0.03 | 0.01 | 0.01 | 0.06 | 0.05 | 0.02 |
| Interest | 0.54 | 0.67 | 0.6 | 0.7 | 0.73 | 0.88 | 1.63 | 1.48 | 1.5 | 0.37 | 0.44 | 0.5 | 0.39 |
| Depreciation | 1.31 | 0.6 | 0.65 | 0.71 | 0.71 | 0.73 | 0.67 | 0.66 | 0.63 | 0.57 | 0.54 | 0.49 | 0.47 |
| PBT | 0.01 | -0.14 | -1.19 | -3.19 | -2.01 | -3.68 | -4 | -2.19 | -1.19 | -1.1 | -1.18 | -0.28 | -0.36 |
| Tax % | 10500% | -128.57% | -35.29% | -21% | -16.42% | -22.83% | 24.25% | 49.32% | 47.06% | 8.18% | 5.08% | 0% | — |
| Net Profit | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 | -0.37 |
| EPS in Rs | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 | -0.37 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
| Reserves | -4.63 | -4.6 | -5.36 | -7.88 | -9.55 | -12.39 | -17.36 | -20.62 | -22.37 | -23.56 | -24.79 | -25.07 |
| Borrowings | 8.16 | 7.51 | 7.57 | 7.71 | 11.24 | 17.92 | 15.52 | 21.08 | 21.4 | 21.52 | 21.58 | 21.53 |
| Other Liabilities | 4.69 | 5.06 | 9.9 | 10.92 | 8.76 | 5.1 | 11.69 | 3.8 | 4.72 | 6.29 | 7.09 | 6.5 |
| Total Liabilities | 18.15 | 17.9 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 | 12.89 |
| Fixed Assets | 8.61 | 8.34 | 9.97 | 9.32 | 8.9 | 8.25 | 7.67 | 7.07 | 6.47 | 5.79 | 5.27 | 4.79 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 9.53 | 9.55 | 12.06 | 11.35 | 11.47 | 12.3 | 12.1 | 7.11 | 7.2 | 8.38 | 8.53 | 8.09 |
| Total Assets | 18.15 | 17.9 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 | 12.89 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -1.43 | 1.35 | -0.96 | 0.8 | -1.92 | -2.88 | 1.11 | -1.01 | 1.2 | 0.17 | 0.51 | 0.58 |
| Investing | -0.88 | -0.34 | -2.05 | -0.08 | -0.29 | 0 | -0.06 | -0.09 | -0.02 | 0.05 | 0 | -0.08 |
| Financing | 0.1 | -1.32 | 3.16 | -0.66 | 2.18 | 2.86 | -1.09 | 1.1 | -1.18 | -0.2 | -0.5 | -0.52 |
| Net Cash Flow | -2.21 | -0.31 | 0.15 | 0.06 | -0.02 | -0.02 | -0.04 | 0 | 0 | 0.02 | 0 | -0.02 |
| Free Cash Flow | -2.3 | 1.03 | -3.24 | 0.74 | -2.21 | -2.96 | 1.02 | -1.07 | 1.17 | 0.26 | 0.49 | 0.57 |
| CFO/OP | -84 | 163 | — | -42 | 315 | 133 | -63 | 1,262 | 129 | -100 | -196 | 88 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73.66 | 53.61 | 84.2 | 66.44 | 67.57 | 128 | 53.33 | 42.15 | 48.03 | 68.6 | 88.43 | 52.53 |
| Inventory Days | 100 | 134 | 130 | 239 | 135 | 324 | 213 | 157 | 348 | 594 | 437 | 338 |
| Days Payable | 112 | 99.3 | 125 | 252 | 140 | 233 | 219 | 86.53 | 150 | 244 | 272 | 222 |
| Cash Conversion Cycle | 62.06 | 88.54 | 88.41 | 52.56 | 62.55 | 219 | 47.49 | 113 | 246 | 419 | 253 | 168 |
| Working Capital Days | 27.75 | 34.84 | -16.06 | -91.18 | -32.55 | -30.73 | -104 | -97.82 | -122 | -203 | -241 | -168 |
| ROCE % | 4.02% | 4.03% | -4.08% | -22.92% | -11.97% | -20.68% | -20.13% | -7.68% | 3.2% | -8.43% | -10.13% | 3.36% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Norris Medicines insights
57 extracted metrics + investor summaries across FY00–FY26.
Documents
2
Closure of Trading Window
26 Mar - Trading window closed from 1 Apr 2026 until 48 hours after audited results for year/quarter ended 31 Mar 2026. 26 Mar - Trading window closed from 1 Apr 2026 until 48 hours after audited results for year/quarter ended 31 Mar 2026.
3
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2 Mar - Schedule of Investor/Analyst Meet to be held on Monday, March 09, 2026. 2 Mar - Schedule of Investor/Analyst Meet to be held on Monday, March 09, 2026.
4
Announcement under Regulation 30 (LODR)-Restructuring
18 Feb - 18 Feb 2026: Sold 38% in Scaleax to DevIT and Aaryan Shah for Rs.3,80,000; ceased being associate. 18 Feb - 18 Feb 2026: Sold 38% in Scaleax to DevIT and Aaryan Shah for Rs.3,80,000; ceased being associate.
5
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14Th February, 2026 Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
14 Feb - Board approved unaudited financial results and limited review for quarter/year ended 31 Dec 2025. 14 Feb - Board approved unaudited financial results and limited review for quarter/year ended 31 Dec 2025.
Frequently Asked Questions about Norris Medicines
What does Norris Medicines Ltd do?
Incorporated in 1990, Norris Medicines
Ltd is a manufacturer of Injections and
Medicinal formulations[1]
Where is Norris Medicines Ltd (524414) listed?
Norris Medicines Ltd trades as NORRISMEDICINESLTD on the NSE and under code 524414 on the BSE.
Which sector does Norris Medicines Ltd belong to?
Norris Medicines Ltd is classified under the Commercial Services sector, in the Trading & Distributors industry.
What is the market capitalisation of Norris Medicines Ltd?
Norris Medicines Ltd has a market capitalisation of ₹15.22 Cr, which places it in the Small Cap band.
What is the PE ratio of Norris Medicines Ltd?
Norris Medicines Ltd trades at a PE ratio of -39.20, on earnings per share of ₹0, against a book value of ₹-15.07 per share.
What is the 52-week high and low of Norris Medicines Ltd?
Over the last 52 weeks Norris Medicines Ltd has traded between ₹12 and ₹19.63.
What is the Return on Equity (ROE) of Norris Medicines Ltd?
Norris Medicines Ltd reported a return on equity of 8.32%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1990, Norris Medicines Ltd is a manufacturer of Injections and Medicinal formulations[1]
Website norrispharma.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524414.md for Norris Medicines Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.